Skip to: Content
Skip to: Site Navigation
Skip to: Search

December 3, 2008 1:31:43 PM CST

Learn about Newser Points »

Lipitor

Lipitor news stories

6 Stories

Deal Delays Generic Lipitor Until 2011

Pact with Indian drug maker stands to net billions for Pfizer

New York Times New York Times Jun 18, 08 5:11 PM CDT
(Newser) - Pfizer has struck a deal with an Indian generic drug maker to delay a cheaper version of Lipitor in the US until November 2011. The agreement limiting generic versions of the cholesterol-lowering drug will translate into billions more in profits for Pfizer, the New York Times reports. Lipitor, the world's best-selling medicine, costs about $3 a day; a generic version will likely be less than $1. More »

Congress
to Probe 'Misleading' Drug Ads

Cholesterol, anemia drugs in spotlight

Wall Street Journal Wall Street Journal May 8, 08 3:10 AM CDT
(Newser) - A congressional panel will examine three ad campaigns as part of a move to tighten regulations on drug companies' direct-to-consumer marketing, the Wall Street Journal reports. The committee will focus on ads for cholesterol drugs Vytorin and Lipitor, and anemia drug Procrit, which has been promoted as an anti-fatigue drug despite FDA demands not to do so. More »

Pfizer Pulls Lipitor Ads
After Probe

Critics accused
pharma giant of
inflating doctor's CV

New York Times New York Times Feb 25, 08 7:55 PM CST
(Newser) - Pfizer said today it will drop its ads for cholesterol drug Lipitor due to criticisms of the TV spots, the New York Times reports. US lawmakers recently probed whether the campaign had inflated the credentials of artificial heart developer Dr. Robert Jarvik. "The way in which we presented Dr. Jarvik in these ads has, unfortunately, led to mis-impressions and distractions," said Pfizer president Ian Read. More »

More about:  Pfizer • Lipitor

Prices Jump for Top Drugs

Drug giants collect now against expected future losses

Wall Street Journal Wall Street Journal Feb 21, 08 4:45 AM CST
(Newser) - Drug companies have slapped a series of huge price hikes on some prescription drugs ahead of drug patent expirations, the Wall Street Journal reports. GlaxoSmithKline has raised the price of antidepressant Wellbutrin 44.5%, while Sanofi-Aventis hiked Ambien's price 70%. Wholesale prices for the top 50 drugs increased an average of nearly 8% last year. More »

Big Pharma Faces Big Plunge

Profits will drop as patents expire, and chemical-based therapies are eclipsed by biotech

Wall Street Journal Wall Street Journal Dec 6, 07 4:50 AM CST
(Newser) - Patent protections on some of the pharmaceutical industry's best-selling drugs, like Lipitor, Plavix and Singulair, are due to expire in the next several years, and drug manufacturers have little in the pipeline to replace them. The drug companies will lose billions—as much as half their combined revenue—to generic competitors, triggering an unprecedented industry crisis, reports the Wall Street Journal . More »

More about:  GlaxoSmithKline • Pfizer • pharmaceutical industry • Eli Lilly • Lipitor • drug manufacturer • Zocor • Merck and Co. • Zyprexa • Fosamax • Singulair • Plavix

Battle Brews in Pharma's Market

Pfizer launches attack on generic drug that threatens Lipitor's dominance

New York Times New York Times Nov 3, 07 6:43 PM CDT
(Newser) - Pfizer is trying to stave off its own heart attack now that its flagship cholesterol-lowering drug Lipitor faces stiff competition from a cheaper generic. Lipitor is still patent-protected, but a very similar drug called Zocor isn't, and since a generic version called simvastatin hit the market, many doctors and insurers are steering patients away from Lipitor to the cheaper alternative, the New York Times says. More »

6 Stories

Today's Most Popular

Loading...

Premium Articles from HighBeam

Find more articles like this

What is Newser?

2008 Codie Finalist

Face it: there's too much news. At Newser a team of editors and writers culls the most important stories from hundreds of U.S. and international sources and reduces them to a headline, picture, and two paragraphs. It's the Newser guarantee: we can take any report or column or video and pack what you need to know into 120 words or less. Newser's short-form aggregation, visual format, and unique information tools help you get more of the kind of news you want, in a quicker and more entertaining way. And we do it 24/7—you can come back morning, noon, night (and in between) for something new that matters. Read less, know more.

Learn more »